




Instance: composition-en-8d5db30b44b1b19f76cd82de873a34e8
InstanceOf: CompositionUvEpi
Title: "Composition for entecavir Package Leaflet"
Description:  "Composition for entecavir Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp8d5db30b44b1b19f76cd82de873a34e8)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - entecavir"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Entecavir Viatris is and what it is used for </li>
<li>What you need to know before you take Entecavir Viatris </li>
<li>How to take Entecavir Viatris </li>
<li>Possible side effects </li>
<li>How to store Entecavir Viatris </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What entecavir is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What entecavir is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Entecavir Viatris tablets are anti-viral medicines, used to treat chronic (long term) hepatitis B 
virus (HBV) infection in adults. Entecavir Viatris can be used in people whose liver is damaged but 
still functions properly (compensated liver disease) and in people whose liver is damaged and does not 
function properly (decompensated liver disease).  </p>
<p>Entecavir Viatris tablets are also used to treat chronic (long term) HBV infection in children 
and adolescents aged 2 years to less than 18 years. Entecavir Viatris can be used in children whose 
liver is damaged but still functions properly (compensated liver disease).  </p>
<p>Infection by the hepatitis B virus can lead to damage to the liver. Entecavir Viatris reduces the amount 
of virus in your body, and improves the condition of the liver.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take entecavir"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take entecavir"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Entecavir Viatris 
* if you are allergic (hypersensitive) to entecavir or any of the other ingredients of this medicine 
(listed in section 6). </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking Entecavir Viatris<br />
* if you have ever had problems with your kidneys, tell your doctor. This is important because 
Entecavir Viatris is eliminated from your body through the kidneys and your dose or dosing 
schedule may need to be adjusted.  </p>
<ul>
<li>
<p>do not stop taking Entecavir Viatris without your doctor s advice since your hepatitis may 
worsen after stopping treatment. When your treatment with Entecavir Viatris is stopped, your 
doctor will continue to monitor you and take blood tests for several months.  </p>
</li>
<li>
<p>discuss with your doctor whether your liver functions properly and, if not, what the possible 
effects on your Entecavir Viatris treatment may be.  </p>
</li>
<li>
<p>if you are also infected with HIV (human immunodeficiency virus) be sure to tell your doctor. 
You should not take Entecavir Viatris to treat your hepatitis B infection unless you are taking 
medicines for HIV at the same time, as the effectiveness of future HIV treatment may be 
reduced. Entecavir Viatris will not control your HIV infection.  </p>
</li>
<li>
<p>taking Entecavir Viatris will not stop you from infecting other people with hepatitis B 
virus (HBV) through sexual contact or body fluids (including blood contamination). So, it is 
important to take appropriate precautions to prevent others from becoming infected with HBV. 
A vaccine is available to protect those at risk from becoming infected with HBV.  </p>
</li>
<li>
<p>Entecavir Viatris belongs to a class of medicines that can cause lactic acidosis (excess of 
lactic acid in your blood) and enlargement of the liver. Symptoms such as nausea, vomiting and 
stomach pain might indicate the development of lactic acidosis. This rare but serious side effect 
has occasionally been fatal. Lactic acidosis occurs more often in women, particularly if they are 
very overweight. Your doctor will monitor you regularly while you are receiving Entecavir 
Viatris.  </p>
</li>
<li>
<p>if you have previously received treatment for chronic hepatitis B, please inform your doctor.  </p>
</li>
</ul>
<p>Children and adolescents<br />
Entecavir Viatris should not be used for children below 2 years of age or weighing less than 10 kg.  </p>
<p>Other medicines and Entecavir Viatris<br />
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines.  </p>
<p>Entecavir Viatris with food and drink<br />
In most cases you may take Entecavir Viatris with or without food. However, if you have had a 
previous treatment with a medicine containing the active substance lamivudine you should consider 
the following. If you were switched over to Entecavir Viatris because the treatment with lamivudine 
was not successful, you should take Entecavir Viatris on an empty stomach once daily. If your liver 
disease is very advanced, your doctor will also instruct you to take Entecavir Viatris on an empty 
stomach. Empty stomach means at least 2 hours after a meal and at least 2 hours before your next 
meal.  </p>
<p>Children and adolescents (from 2 to less than 18 years of age) can take Entecavir Viatris with or 
without food.  </p>
<p>Pregnancy, breast-feeding and fertility<br />
Tell your doctor if you are pregnant or planning to become pregnant. It has not been demonstrated that 
entecavir is safe to use during pregnancy. Entecavir Viatris must not be used during pregnancy unless 
specifically directed by your doctor. It is important that women of childbearing age receiving 
treatment with Entecavir Viatris use an effective method of contraception to avoid becoming pregnant.  </p>
<p>You should not breast-feed during treatment with Entecavir Viatris. Tell your doctor if you are 
breastfeeding. It is not known whether entecavir, the active substance in Entecavir Viatris, is excreted 
in human breast milk.  </p>
<p>Driving and using machines<br />
Dizziness, tiredness (fatigue) and sleepiness (somnolence) are common side effects which may impair 
your ability to drive and use machines. If you have any concerns consult your doctor.  </p>
<p>Entecavir Viatris contains lactose<br />
This medicine contains lactose. If you have been told by your doctor that you have an intolerance to 
some sugars, contact your doctor before taking this medicine. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take entecavir"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take entecavir"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Not all patients need to take the same dose of Entecavir Viatris.  </p>
<p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure.   </p>
<p>For adults the recommended dose is either 0.5 mg or 1 mg once daily orally (by mouth).  </p>
<p>Your dose will depend on:<br />
<em> whether you have been treated for HBV infection before, and what medicine you received.<br />
</em> whether you have kidney problems. Your doctor may prescribe a lower dose for you or instruct 
you to take it less often than once a day.<br />
* the condition of your liver.  </p>
<p>For children and adolescents (from 2 to less than 18 years of age), your child's doctor will decide the 
right dose based on your child's weight. Children weighing at least 32.6 kg may take the 0.5 mg tablet 
or an entecavir oral solution may be available. For patients weighing from 10 kg to 32.5 kg, an 
entecavir oral solution is recommended. All doses should be taken once daily orally (by mouth). There 
are no recommendations for entecavir in children less than 2 years of age or weighing less than 10 kg.  </p>
<p>For children and adolescents (from 2 to less than 18 years of age), Entecavir Viatris 0.5 mg Film-
coated Tablets are available or an oral solution may be available. Your child s doctor will decide the 
right dose based on your child s weight. </p>
<p>Your doctor will advise you on the dose that is right for you.<br />
Always take the dose recommended by your doctor to ensure that your medicine is fully effective and 
to reduce the development of resistance to treatment. Take Entecavir Viatris as long as your doctor has 
told you. Your doctor will tell you if and when you should stop the treatment.  </p>
<p>Some patients must take Entecavir Viatris on an empty stomach (see Entecavir Viatris with food and 
drink in Section 2). If your doctor instructs you to take Entecavir Viatris on an empty stomach, empty 
stomach means at least 2 hours after a meal and at least 2 hours before your next meal.  </p>
<p>If you take more Entecavir Viatris than you should<br />
Contact your doctor at once.  </p>
<p>If you forget to take Entecavir Viatris<br />
It is important that you do not miss any doses. If you miss a dose of Entecavir Viatris, take it as soon 
as possible, and then take your next scheduled dose at its regular time. If it is almost time for your next 
dose, do not take the missed dose. Wait and take the next dose at the regular time. Do not take a 
double dose to make up for a forgotten dose.  </p>
<p>Do not stop Entecavir Viatris without your doctor s advice<br />
Some people get very serious hepatitis symptoms when they stop taking entecavir. Tell your doctor 
immediately about any changes in symptoms that you notice after stopping treatment.  </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Patients treated with entecavir have reported the following side effects:  </p>
<p>Adults </p>
<p>Common (at least 1 in 100 patients): headache, insomnia (inability to sleep), fatigue (extreme 
tiredness), dizziness, somnolence (sleepiness), vomiting, diarrhoea, nausea, dyspepsia 
(indigestion), and increased blood levels of liver enzymes.  </p>
<p>Uncommon (at least 1 in 1,000 patients): rash, hair loss.  </p>
<p>Rare (at least 1 in 10,000 patients): severe allergic reaction.  </p>
<p>Children and adolescents 
The side effects experienced in children and adolescents are similar to those experienced in adults as 
described above with the following difference: 
Very common (at least 1 in 10 patients): low levels of neutrophils (one type of white blood cells, 
which are important in fighting infection). </p>
<p>Reporting of side effects<br />
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store entecavir"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store entecavir"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the bottle, blister or carton after EXP. 
The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions.  </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Entecavir Viatris contains  </p>
<p>Entecavir Viatris 0.5 mg film-coated tablets 
The active substance is entecavir. Each film-coated tablet contains entecavir monohydrate equivalent 
to 0.5 mg entecavir.  </p>
<p>Entecavir Viatris1 mg film-coated tablets 
The active substance is entecavir. Each film-coated tablet contains entecavir monohydrate equivalent 
to 1 mg entecavir.  </p>
<p>The other ingredients are: 
Tablet core: microcrystalline cellulose, crospovidone, lactose monohydrate (see section 2,  Entacavir 
Viatris contains lactose ), magnesium stearate 
Tablet coating: titanium dioxide (E171), hypromellose, macrogol 400, polysorbate 80. What Entecavir Viatris looks like and contents of the pack </p>
<p>Entecavir Viatris 0.5 mg film-coated tablets 
The film-coated tablets (tablets) are white, film-coated, round, biconvex, beveled edge tablet debossed 
with  M  on one side and  EA  on the other side. </p>
<p>Entecavir Viatris 1 mg film-coated tablets 
The film-coated tablets (tablets) are white, film-coated, round, biconvex, beveled edge tablet debossed 
with  M  on one side and  EB  on the other side. </p>
<p>Entecavir Viatris film-coated tablets are supplied in blisters packs containing 30 tablets, perforated 
blister packs containing 30 x 1 or 90 x 1 tablets, and in bottles containing 30 or 90 tablets. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder<br />
Mylan Pharmaceuticals Limited 
Damastown Industrial Park,<br />
Mulhuddart, Dublin 15,<br />
DUBLIN 
Ireland </p>
<p>Manufacturer 
McDermott Laboratories Limited t/a Gerard Laboratories 
Unit 35/36 Baldoyle Industrial Estate, 
Grange Road, Dublin Ireland </p>
<p>Mylan Hungary Kft. 
Mylan utca 1, 
Kom rom - 2Hungary </p>
<p>Mylan Germany GmbH<br />
Zweigniederlassung Bad Homburg v. d. Hoehe, Benzstrasse 1<br />
Bad Homburg v. d. Hoehe<br />
Hessen, 61352,<br />
Germany </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Mylan bvba/sprl 
T l/Tel: + 32 (0)2 658 61 Lietuva 
Mylan Healthcare UAB 
Tel: + 370 5 205 1  </p>
<p>Te .: + 359 2 44 55 Luxembourg/Luxemburg 
Mylan bvba/sprl 
T l/Tel: + 32 (0)2 658 61 (Belgique/Belgien) 
 esk  republika 
Viatris CZ s.r.o. 
Tel: + 420 222 004 Magyarorsz g 
Mylan EPD Kft. 
Tel.: + 36 1 465 2Danmark 
Viatris ApS 
Tlf: + 45 28 11 69 Malta 
V.J. Salomone Pharma Ltd 
Tel: + 356 21 22 01 Deutschland 
Viatris Healthcare GmbH<br />
Tel: + 49 800 0700 Nederland 
Mylan BV 
Tel: + 31 (0)20 426 3Eesti 
BGP Products Switzerland GmbH Eesti filiaal<br />
Tel: + 372 6363 Norge 
Viatris AS 
Tlf: + 47 66 75 33  <br />
Generics Pharma Hellas  <br />
 : + 30 210 993 6 sterreich 
Arcana Arzneimittel GmbH 
Tel: + 43 1 416 2Espa a 
Viatris Pharmaceuticals, S.L.U. 
Tel: + 34 900 102 Polska 
Mylan Healthcare Sp. z.o.o. 
Tel.: + 48 22 546 64 France 
Viatris Sant<br />
T l: + 33 4 37 25 75 Portugal 
Mylan, Lda. 
Tel: + 351 214 127 Hrvatska 
Viatris Hrvatska d.o.o.<br />
Tel: + 385 1 23 50 Rom nia 
BGP Products SRL 
Tel: + 40 372 579 Ireland 
Mylan Ireland Limited 
Tel: + 353 1 8711Slovenija 
Viatris d.o.o. 
Tel: + 386 1 23 63  sland 
Icepharma hf. 
S mi: + 354 540 8Slovensk  republika 
Viatris Slovakia s.r.o. 
Tel: + 421 2 32 199 Italia 
Mylan Italia S.r.l. 
Tel: + 39 02 612 46Suomi/Finland 
Viatris Oy 
Puh/Tel: + 358 20 720 9<br />
Varnavas Hadjipanayis Ltd<br />
 : + 357 2220 7Sverige 
Viatris AB<br />
Tel: + 46 (0)8 630 19 Latvija 
Mylan Healthcare SIA<br />
Tel: + 371 676 055 United Kingdom (Northern Ireland) 
Mylan IRE Healthcare Limited 
Tel: + 353 18711This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-8d5db30b44b1b19f76cd82de873a34e8
InstanceOf: CompositionUvEpi
Title: "Composition for entecavir Package Leaflet"
Description:  "Composition for entecavir Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp8d5db30b44b1b19f76cd82de873a34e8)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - entecavir"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse<br />
2. Det skal du vide, før du begynder at tage Entecavir Viatris 
3. Sådan skal du tage Entecavir Viatris 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What entecavir is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What entecavir is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Entecavir Viatris tabletter er anti-viral medicin, som anvendes til at behandle kronisk 
(vedvarende) infektion med hepatitis-B virus (HBV) hos voksne. Entecavir Viatris kan anvendes til 
mennesker, hvis lever er skadet, men stadig fungerer ordentligt (kompenseret leversygdom) og til 
mennesker, hvis lever er skadet og ikke fungerer ordentligt (inkompenseret leversygdom). </p>
<p>Entecavir Viatris tabletter anvendes også til at behandle kronisk (vedvarende) infektion med 
HBV hos børn og unge i alderen 2-18 år. Entecavir Viatris kan anvendes til børn, hvis lever er 
skadet, men stadig fungerer ordentligt (kompenseret leversygdom). </p>
<p>Infektion med hepatitis-B virus kan medføre leverskader. Entecavir Viatris mindsker mængden af 
virus i kroppen og forbedrer leverens tilstand </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take entecavir"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take entecavir"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Entecavir Viatris 
- hvis du er allergisk over for entecavir eller et af de øvrige indholdsstoffer i dette lægemiddel 
(angivet i afsnit 6). </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager Entecavir Viatris </p>
<ul>
<li>
<p>hvis du tidligere har haft problemer med nyrerne, skal du fortælle din læge det. Det er 
vigtigt, fordi Entecavir Viatris udskilles gennem nyrerne, og din dosis eller dosisintervallet skal 
tilpasses. </p>
</li>
<li>
<p>du skal ikke holde op med at tage Entecavir Viatris uden at have talt med din læge om det 
først, da din hepatitis kan forværres, efter at behandlingen stoppes. Hvis behandlingen med 
Entecavir Viatris skal stoppes, vil din læge følge dig og tage blodprøver igennem flere måneder. </p>
</li>
<li>
<p>tal med lægen om din lever fungerer ordentligt, og hvis ikke, find ud af, hvordan det kan 
påvirke din behandling med Entecavir Viatris. </p>
</li>
<li>
<p>hvis du også har en hiv-infektion (humant immundefektvirus), skal du sørge for at fortælle det 
til din læge. Du bør ikke tage Entecavir Viatris for at behandle din hepatitis-B-infektion, 
medmindre du samtidig også tager medicin mod hiv, idet virkningen af fremtidig hiv-
behandling kan blive nedsat. Entecavir Viatris vil ikke kontrollere din hiv-infektion. </p>
</li>
<li>
<p>selvom du tager Entecavir Viatris, kan du stadig smitte andre med hepatitis-B virus 
(HBV) gennem seksuel kontakt eller kropsvæsker (fx blod). Så det er vigtigt, at du overholder 
relevante forholdsregler for at undgå at smitte andre med HBV. Det er muligt at blive vaccineret 
mod HBV. </p>
</li>
<li>
<p>Entecavir Viatris tilhører en gruppe medicin, der kan forårsage lactacidose (ophobning af 
mælkesyre i blodet) og forstørret lever. Kvalme, opkastning og mavesmerter kan være tegn på 
udvikling af lactacidose. Denne sjældne, men alvorlige bivirkning har i nogle tilfælde været 
dødelig. Kvinder har større risiko for lactacidose, specielt hvis de er meget overvægtige. Lægen 
vil jævnligt kontrollere dig, mens du tager Entecavir Viatris. </p>
</li>
<li>
<p>tal med lægen, hvis du tidligere har modtaget behandling for kronisk hepatitis B. </p>
</li>
</ul>
<p>Børn og unge 
Entecavir Viatris bør ikke anvendes til børn under 2 år eller børn, der vejer under 10 kg.  </p>
<p>Brug af anden medicin sammen med Entecavir Viatris<br />
Fortæl altid til lægen eller apotekspersonalet, hvis du bruger anden medicin, for nylig har brugt anden 
medicin eller planlægger at bruge anden medicin. Dette gælder også medicin, som ikke er købt på 
recept, f.eks. naturlægemidler og vitaminer og mineraler. </p>
<p>Brug af Entecavir Viatris sammen med mad og drikke 
De fleste kan tage Entecavir Viatris med eller uden mad. Hvis du tidligere har fået medicin, der 
indeholder det aktive stof lamivudin, skal du dog være opmærksom på følgende: Hvis du er skiftet til 
Entecavir Viatris, fordi behandlingen med lamivudin ikke virkede, skal du tage Entecavir Viatris på 
tom mave, én gang dagligt. Hvis din leversygdom er meget fremskreden, vil lægen ligeledes vejlede 
dig i, at du skal tage Entecavir Viatris på tom mave. Tom mave betyder mindst 2 timer efter et måltid 
og mindst 2 timer før det næste måltid. </p>
<p>Børn og unge (fra 2-18 år) kan tage Entecavir Viatris med eller uden mad. </p>
<p>Graviditet, amning og frugtbarhed 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. Det vides ikke, om 
det er sikkert at bruge Entecavir Viatris under graviditet. Entecavir Viatris må ikke anvendes under 
graviditet undtagen, hvis lægen har ordineret det til dig. Det er vigtigt, at frugtbare kvinder, som er i 
behandling med Entecavir Viatris, anvender effektiv svangerskabsforebyggelse for at forhindre 
graviditet. </p>
<p>Du må ikke amme, mens du er i behandling med Entecavir Viatris. Fortæl det til lægen, hvis du 
ammer. Det vides ikke om entecavir, der er det aktive stof i Entecavir Viatris, udskilles i mælken. </p>
<p>Trafik- og arbejdssikkerhed 
Svimmelhed, voldsom træthed og søvnighed er almindelige bivirkninger, som kan påvirke evnen til at 
køre bil, motorcykel eller cykle eller arbejde med værktøj eller maskiner. Hvis du har spørgsmål, kan 
du kontakte lægen. </p>
<p>Entecavir Viatris indeholder lactose 
Dette lægemiddel indeholder lactose. Kontakt lægen, før du tager dette lægemiddel, hvis lægen har 
fortalt dig, at du ikke tåler visse sukkerarter. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take entecavir"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take entecavir"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dosis af Entecavir Viatris er ikke den samme til alle patienter. </p>
<p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Til voksne er den anbefalede dosis 0,5 mg eller 1 mg én gang dagligt oralt (igennem munden).  </p>
<p>Din dosis afhænger af: </p>
<ul>
<li>
<p>om du tidligere er behandlet for HBV-infektion, og hvilken medicin du fik. </p>
</li>
<li>
<p>om du har nyreproblemer. Lægen kan vælge at give dig en lavere dosis eller vejlede dig i at tage 
medicinen mindre end en gang dagligt.  </p>
</li>
<li>
<p>tilstanden af din lever. </p>
</li>
</ul>
<p>Brug til børn og unge (fra 2-18 år). Barnets læge vil fastsætte den korrekte dosis ud fra barnets vægt. 
Børn, der vejer mindst 32,6 kg kan bruge 0,5 tabletten, eller der findes en en oral opløsning. Til 
patienter, der vejer fra 10-32,5 kg findes der en oral opløsning. Alle doseringer tages én gang dagligt 
oralt (igennem munden). Der er ingen dosisanbefalinger for entecavir til børn under 2 år eller børn, der 
vejer under 10 kg. </p>
<p>Brug til børn og unge (fra 2-18 år). Entecavir Viatris findes som 0,5 mg filmovertrukne tabletter, 
eller der findes en oral opløsning. Barnets læge vil fastsætte den korrekte dosis ud fra barnets vægt. </p>
<p>Lægen vil rådgive dig om, hvilken dosis, der er bedst for dig.<br />
Tag altid den dosis, lægen anbefaler for at være sikker på, at medicinen virker helt som den skal og for 
at mindske udviklingen af resistens. Tag Entecavir Viatris lige så længe som lægen har foreskrevet. 
Lægen vil give dig besked om, hvorvidt du skal afslutte behandingen, og hvornår du skal afslutte 
behandlingen. </p>
<p>Nogle patienter skal tage Entecavir Viatris på tom mave (se Brug af Entecavir Viatris sammen med 
mad og drikke i afsnit 2). Hvis lægen har sagt, at du skal tage Entecavir Viatris på tom mave, betyder 
det mindst 2 timer efter et måltid og mindst 2 timer før næste måltid. </p>
<p>Hvis du har taget for meget Entecavir Viatris 
Du skal straks kontakte lægen. </p>
<p>Hvis du har glemt at tage Entecavir Viatris 
Det er vigtigt, at du ikke springer en dosis over. Hvis du glemmer at tage en dosis af Entecavir Viatris, 
skal du tage den så hurtigt som muligt, og herefter tage næste dosis til sædvanlig tid. Hvis det næsten 
er tid til næste dosis, skal du ikke tage den glemte dosis, men vente og tage næste dosis til sædvanlig 
tid. Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Hvis du holder op med at tage Entecavir Viatris 
Nogle mennesker får meget alvorlige leversymptomer, når de holder op med at tage entecavir. Hvis du 
bemærker ændringer i symptomer, efter at behandlingen er stoppet, skal du straks fortælle det til 
lægen. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om.  </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Patienter behandlet med entecavir har indberettet følgende bivirkninger: </p>
<p>Voksne  </p>
<ul>
<li>
<p>Almindelig (kan forekomme hos mindst 1 ud af 100 patienter): hovedpine, søvnløshed, voldsom 
træthed, svimmelhed, søvnighed, opkastning, diarré, kvalme, fordøjelsesbesvær og forhøjet 
indhold af leverenzymer i blodet.  </p>
</li>
<li>
<p>Ikke almindelig (kan forekomme hos mindst 1 ud af 1.000 patienter): udslæt, hårtab.  </p>
</li>
<li>
<p>Sjælden (kan forekomme hos mindst 1 ud af 10.000 patienter): alvorlig allergisk reaktion. </p>
</li>
</ul>
<p>Børn og unge 
De bivirkninger, der er set hos børn og unge, svarer til dem, der er set hos voksne som beskrevet 
ovenfor med følgende forskel: 
Meget almindelige (kan forekomme hos mindst 1 ud af 10 patienter): lave niveauer af neutrofiler (en 
type hvide blodlegemer, der er vigtige til bekæmpelse af infektion). </p>
<p>Tal med lægen eller apotekspersonalet, hvis du får bivirkninger, herunder bivirkninger, som ikke 
fremgår af denne indlægsseddel. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejerske. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store entecavir"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store entecavir"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Tag ikke lægemidlet efter den udløbsdato, der står på beholderen, blisterarket eller pakningen efter 
Exp. Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Entecavir Viatris indeholder: </p>
<p>Entecavir Viatris 0,5 mg filmovertrukne tabletter 
Aktivt stof: entecavir. Hver filmovertrukket tablet indeholder entecavirmonohydrat svarende til 0,5 mg 
entecavir. </p>
<p>Entecavir Viatris 1 mg filmovertrukne tabletter 
Aktivt stof: entecavir. Hver filmovertrukket tablet indeholder entecavirmonohydrat svarende til 1 mg 
entecavir. </p>
<p>Øvrige indholdsstoffer: 
Tabletkerne: Mikrokrystallinsk cellulose, crospovidon, lactosemonohydrat (se afsnit 2 “Entecavir 
Viatris indeholder lactose"), magnesiumstearat 
Tabletovertræk: Titandioxid (E171), hypromellose, macrogol 400, polysorbat 80. Udseende og pakningsstørrelser </p>
<p>Entecavir Viatris 0,5 mg filmovertrukne tabletter 
De filmovertrukne tabletter (tabletter) er hvide, filmovertrukne, runde, bikonvekse tabletter med 
afrundet kant og præget med "M" på den ene side og "EA" på den anden side.  </p>
<p>Entecavir Viatris 1 mg filmovertrukne tabletter 
De filmovertrukne tabletter (tabletter) er hvide, filmovertrukne, runde, bikonvekse tabletter med 
afrundet kant og præget med "M" på den ene side og "EB" på den anden side.  </p>
<p>Entecavir Viatris filmovertrukne tabletter fås i blisterpakninger med 30 tabletter, perforerede 
blisterpakninger med 30 x 1 eller 90 x 1 tabletter og i beholdere med 30 eller 90 tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen<br />
Viatris Limited 
Damastown Industrial Park,<br />
Mulhuddart, Dublin 15,<br />
DUBLIN 
Irland </p>
<p>Fremstiller 
McDermott Laboratories Limited t/a Gerard Laboratories 
Unit 35/36 Baldoyle Industrial Estate, 
Grange Road, Dublin Irland </p>
<p>Mylan Hungary Kft. 
Mylan utca 1, 
Komárom - 2Ungarn </p>
<p>Mylan Germany GmbH<br />
Zweigniederlassung Bad Homburg v. d. Hoehe, Benzstrasse 1<br />
Bad Homburg v. d. Hoehe<br />
Hessen, 61352,<br />
Tyskland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Viatris 
Tél/Tel: + 32 (0)2 658 61<br />
Lietuva 
Viatris UAB<br />
Tel: +370 5 205 1 
България 
Майлан ЕООД 
Тел.: +359 2 44 55<br />
Luxembourg/Luxemburg 
Viatris </p>
<p>Tél/Tel: + 32 (0)2 658 61 (Belgique/Belgien) </p>
<p>Česká republika 
Viatris CZ s.r.o. 
Tel: + 420 222 004<br />
Magyarország 
Viatris Healthcare Kft. 
Tel.: + 36 1 465 2 
Danmark 
Viatris ApS 
Tlf: +45 28 11 69<br />
Malta 
V.J. Salomone Pharma Ltd 
Tel: + 356 21 22 01<br />
Deutschland 
Viatris Healthcare GmbH<br />
Tel: +49 800 0700<br />
Nederland 
Mylan BV 
Tel: +31 (0)20 426 3Eesti 
Viatris OÜ<br />
Tel: + 372 6363<br />
Norge 
Viatris AS 
Tlf: + 47 66 75 33<br />
Ελλάδα<br />
Viatris Hellas Ltd<br />
Τηλ: +30 2100 100 02  </p>
<p>Österreich 
Arcana Arzneimittel GmbH 
Tel: +43 1 416 2 
España 
Viatris Pharmaceuticals, S.L. 
Tel: + 34 900 102<br />
Polska 
Viatris Healthcare Sp. z o.o. 
Tel: + 48 22 546 64<br />
France 
Viatris Santé 
Tél: +33 4 37 25 75<br />
Portugal 
Mylan, Lda. 
Tel: + 351 214 127<br />
Hrvatska 
Viatris Hrvatska d.o.o. <br />
Tel: +385 1 23 50<br />
România 
BGP Products SRL 
Tel: +40 372 579<br />
Ireland 
Mylan Ireland Limited 
Tel: +353 1 8711 
Slovenija 
Viatris d.o.o. 
Tel: + 386 1 23 63<br />
Ísland 
Icepharma hf. 
Sími: +354 540 8 
Slovenská republika 
Viatris Slovakia s.r.o. 
Tel: +421 2 32 199 Italia 
Viatris Italia S.r.l.<br />
Tel: + 39 (0) 2 612 46 
Suomi/Finland 
Viatris Oy 
Puh/Tel: +358 20 720 9 
Κύπρος 
GPA Pharmaceuticals Ltd<br />
Τηλ: +357 22863100  </p>
<p>Sverige 
Viatris AB<br />
Tel: +46 (0)8 630 19<br />
Latvija 
Viatris SIA<br />
Tel: +371 676 055<br />
United Kingdom (Northern Ireland) 
Mylan IRE Healthcare Limited 
Tel: +353 18711 </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-8d5db30b44b1b19f76cd82de873a34e8
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for entecavir Package Leaflet for language en"
Description: "ePI document Bundle for entecavir Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-8d5db30b44b1b19f76cd82de873a34e8"
* entry[0].resource = composition-en-8d5db30b44b1b19f76cd82de873a34e8

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp8d5db30b44b1b19f76cd82de873a34e8"
* entry[=].resource = mp8d5db30b44b1b19f76cd82de873a34e8
                            
                    
Instance: bundlepackageleaflet-da-8d5db30b44b1b19f76cd82de873a34e8
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for entecavir Package Leaflet for language da"
Description: "ePI document Bundle for entecavir Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-8d5db30b44b1b19f76cd82de873a34e8"
* entry[0].resource = composition-da-8d5db30b44b1b19f76cd82de873a34e8

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp8d5db30b44b1b19f76cd82de873a34e8"
* entry[=].resource = mp8d5db30b44b1b19f76cd82de873a34e8
                            
                    



Instance: mp8d5db30b44b1b19f76cd82de873a34e8
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Entecavir Viatris 0.5 mg film-coated tablets"
Description: "Entecavir Viatris 0.5 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/17/1227/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Entecavir Viatris 0.5 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 8d5db30b44b1b19f76cd82de873a34e8ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "entecavir"

* status = #current
* mode = #working

* title = "List of all ePIs associated with entecavir"

* subject = Reference(mp8d5db30b44b1b19f76cd82de873a34e8)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#entecavir "entecavir"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-8d5db30b44b1b19f76cd82de873a34e8) // entecavir en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-8d5db30b44b1b19f76cd82de873a34e8) // entecavir da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-8d5db30b44b1b19f76cd82de873a34e8
InstanceOf: List

* insert 8d5db30b44b1b19f76cd82de873a34e8ListRuleset
    